Multiple Myeloma and EasyM Resource Centre.
Featured
Mass Spectrometry Testing in Multiple Myeloma
wtang@rapidnovor.com2025-02-18T14:47:53-05:00February 11th, 2025|Articles|
M-spike and Multiple Myeloma
wtang@rapidnovor.com2025-02-18T14:49:47-05:00February 5th, 2025|Articles|
Comparison of EasyM Clonotypic Mass Spectrometry and EuroFlow MRD in Multiple Myeloma
wtang@rapidnovor.com2025-02-18T16:57:33-05:00November 7th, 2024|Publication|
Publications, Posters & Case Studies
wtang@rapidnovor.com2025-02-18T16:57:33-05:00
Comparison of EasyM Clonotypic Mass Spectrometry and EuroFlow MRD in Multiple Myeloma
wtang@rapidnovor.com2025-02-18T16:57:33-05:00November 7th, 2024|Publication|
wtang@rapidnovor.com2025-02-19T15:32:29-05:00
Novel Assay for Quantification of Free Light Chain (FLC) Dimers in Serum of Patients with Plasma Cell Dyscrasias
wtang@rapidnovor.com2025-02-19T15:32:29-05:00December 17th, 2023|Poster|
wtang@rapidnovor.com2025-02-19T14:30:19-05:00
Measurable Residual Disease Status By Clonotypic Mass Spectrometry with EasyM Assay Predicts Outcomes Following AHCT in Multiple Myeloma
wtang@rapidnovor.com2025-02-19T14:30:19-05:00December 15th, 2023|Poster|
Articles
wtang@rapidnovor.com2025-02-18T14:47:53-05:00
Mass Spectrometry Testing in Multiple Myeloma
wtang@rapidnovor.com2025-02-18T14:47:53-05:00February 11th, 2025|
wtang@rapidnovor.com2025-02-18T14:49:47-05:00
M-spike and Multiple Myeloma
wtang@rapidnovor.com2025-02-18T14:49:47-05:00February 5th, 2025|
Press & News
wtang@rapidnovor.com2025-02-11T16:24:47-05:00
Rapid Novor Teams Up with PMCC to Evaluate EasyM™ for Multiple Myeloma Minimal Residual Disease Monitoring
wtang@rapidnovor.com2025-02-11T16:24:47-05:00May 14th, 2024|
wtang@rapidnovor.com2025-02-11T16:25:14-05:00
Rapid Novor’s Blood Test for Multiple Myeloma Monitoring is CLIA Certified for Clinical Use in the US
wtang@rapidnovor.com2025-02-11T16:25:14-05:00March 16th, 2023|